AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
Log in

NASDAQ:CURNeuralstem News Headlines

$0.73
0.00 (0.00 %)
(As of 07/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.70
Now: $0.73
$0.76
50-Day Range
$0.72
MA: $0.84
$0.96
52-Week Range
$1.10
Now: $0.73
$13.78
Volume449,523 shs
Average Volume1.98 million shs
Market Capitalization$1.54 million
P/E RatioN/A
Dividend YieldN/A
Beta1.81

Headlines

Neuralstem (NASDAQ CUR) News Headlines

Source:
DateHeadline
ReNeuron Signs New Exosome Research Collaboration - PRNewswireReNeuron Signs New Exosome Research Collaboration - PRNewswire
www.prnewswire.com - June 25 at 7:22 AM
Neuralstem (NASDAQ:CUR) Getting Very Critical News Coverage, InfoTrie ReportsNeuralstem (NASDAQ:CUR) Getting Very Critical News Coverage, InfoTrie Reports
www.americanbankingnews.com - June 16 at 4:06 AM
HKBU invents nanostructure that stimulates growth of stem cells for Parkinsons disease treatment - PRNewswireHKBU invents nanostructure that stimulates growth of stem cells for Parkinson's disease treatment - PRNewswire
www.prnewswire.com - May 22 at 12:09 AM
Connectyx Welcomes I. Richard Garr, Esq. to Companys Scientific Advisory Board - GlobeNewswireConnectyx Welcomes I. Richard Garr, Esq. to Company's Scientific Advisory Board - GlobeNewswire
www.globenewswire.com - May 19 at 5:02 PM
Connectyx Welcomes I. Richard Garr, Esq. to Company’s Scientific Advisory Board - Yahoo FinanceConnectyx Welcomes I. Richard Garr, Esq. to Company’s Scientific Advisory Board - Yahoo Finance
finance.yahoo.com - May 19 at 12:02 PM
ReNeuron Announces CTX Cell Line Shows Further Potential - PRNewswireReNeuron Announces CTX Cell Line Shows Further Potential - PRNewswire
www.prnewswire.com - May 7 at 8:45 AM
Stem Cells Market To Reach USD 17.78 Billion By 2027 | Reports and Data - GlobeNewswireStem Cells Market To Reach USD 17.78 Billion By 2027 | Reports and Data - GlobeNewswire
www.globenewswire.com - May 4 at 4:17 PM
ReNeuron Announces Exosome Research Collaboration - Yahoo FinanceReNeuron Announces Exosome Research Collaboration - Yahoo Finance
finance.yahoo.com - April 8 at 7:50 AM
AgeX Therapeutics Reports Fourth Quarter and Annual 2019 Financial Results and Provides Business Update - Business WireAgeX Therapeutics Reports Fourth Quarter and Annual 2019 Financial Results and Provides Business Update - Business Wire
www.businesswire.com - March 30 at 9:05 PM
Stem cell-combo therapy could bring long-term relief for gastroparesis - Yahoo FinanceStem cell-combo therapy could bring long-term relief for gastroparesis - Yahoo Finance
finance.yahoo.com - March 18 at 11:42 PM
Growth factor-modified stem cells help repair spinal cord injuries in rats - Yahoo FinanceGrowth factor-modified stem cells help repair spinal cord injuries in rats - Yahoo Finance
finance.yahoo.com - February 19 at 12:30 PM
ReNeuron Announces Publication of Positive Phase 2a Stroke Clinical Data - PRNewswireReNeuron Announces Publication of Positive Phase 2a Stroke Clinical Data - PRNewswire
www.prnewswire.com - February 18 at 7:24 PM
AgeX Therapeutics to Collaborate with University of California, Irvine on Neural Stem Cell Research Program for Huntington’s Disease and Other Neurological Disorders - Yahoo FinanceAgeX Therapeutics to Collaborate with University of California, Irvine on Neural Stem Cell Research Program for Huntington’s Disease and Other Neurological Disorders - Yahoo Finance
finance.yahoo.com - February 3 at 12:24 PM
Form 8-K Neuralstem, Inc. For: Jan 23 - StreetInsider.comForm 8-K Neuralstem, Inc. For: Jan 23 - StreetInsider.com
www.streetinsider.com - January 23 at 1:18 PM
Seneca Biopharma rockets 129% on cell therapy promise - Seeking AlphaSeneca Biopharma rockets 129% on cell therapy promise - Seeking Alpha
seekingalpha.com - January 17 at 12:57 PM
Neuralstem Stock Plunges After Latest Study on ALS DrugNeuralstem Stock Plunges After Latest Study on ALS Drug
www.thestreet.com - November 24 at 8:54 AM
Form 8-K Neuralstem, Inc. For: Nov 14 - StreetInsider.comForm 8-K Neuralstem, Inc. For: Nov 14 - StreetInsider.com
www.streetinsider.com - November 15 at 5:29 PM
Form 10-Q Neuralstem, Inc. For: Sep 30 - StreetInsider.comForm 10-Q Neuralstem, Inc. For: Sep 30 - StreetInsider.com
www.streetinsider.com - November 14 at 11:24 AM
Neuralstem leads healthcare gainers; Cyclerion Therapeutics tops the losers - Seeking AlphaNeuralstem leads healthcare gainers; Cyclerion Therapeutics tops the losers - Seeking Alpha
seekingalpha.com - October 30 at 1:57 PM
Seneca Biopharma up 47% on expected pipeline expansion - Seeking AlphaSeneca Biopharma up 47% on expected pipeline expansion - Seeking Alpha
seekingalpha.com - October 30 at 1:57 PM
Seneca Biopharma and QYuns Therapeutics Sign Term Sheet for Global Licensing of Novel Monoclonal Antibodies for Treating Auto-Immune Diseases - PRNewswireSeneca Biopharma and QYuns Therapeutics Sign Term Sheet for Global Licensing of Novel Monoclonal Antibodies for Treating Auto-Immune Diseases - PRNewswire
www.prnewswire.com - October 30 at 8:57 AM
Seneca Biopharma and QYuns Therapeutics Sign Term Sheet for Global Licensing of Novel Monoclonal Antibodies for Treating Auto-Immune DiseasesSeneca Biopharma and QYuns Therapeutics Sign Term Sheet for Global Licensing of Novel Monoclonal Antibodies for Treating Auto-Immune Diseases
finance.yahoo.com - October 30 at 8:57 AM
Local biopharma rebrands as part of commercialization strategy - Washington Business JournalLocal biopharma rebrands as part of commercialization strategy - Washington Business Journal
www.bizjournals.com - October 29 at 11:22 PM
Local biopharma rebrands as part of commercialization strategyLocal biopharma rebrands as part of commercialization strategy
finance.yahoo.com - October 29 at 6:22 PM
Seneca Biopharma to Present at the 7th China Renaissance Healthcare and Life Sciences Leadership Summit - PRNewswireSeneca Biopharma to Present at the 7th China Renaissance Healthcare and Life Sciences Leadership Summit - PRNewswire
www.prnewswire.com - October 28 at 11:28 PM
Seneca Biopharma to Present at the 7th China Renaissance Healthcare and Life Sciences Leadership SummitSeneca Biopharma to Present at the 7th China Renaissance Healthcare and Life Sciences Leadership Summit
finance.yahoo.com - October 28 at 11:28 PM
Neuralstem becomes Seneca Biopharma - Seeking AlphaNeuralstem becomes Seneca Biopharma - Seeking Alpha
seekingalpha.com - October 28 at 1:27 PM
Neuralstem Becomes Seneca BiopharmaNeuralstem Becomes Seneca Biopharma
finance.yahoo.com - October 28 at 1:27 PM
ReNeuron Presents Positive Data at the 27th Annual Congress of the European Society of Gene and Cell Therapy on Lead Cell Line - PRNewswireReNeuron Presents Positive Data at the 27th Annual Congress of the European Society of Gene and Cell Therapy on Lead Cell Line - PRNewswire
www.prnewswire.com - October 23 at 10:21 PM
Neuralstem Announces Adjustment to Inducement Grant Under Nasdaq Listing Rule 5636(c)(4)Neuralstem Announces Adjustment to Inducement Grant Under Nasdaq Listing Rule 5636(c)(4)
finance.yahoo.com - October 14 at 1:10 PM
The Daily Biotech Pulse: FDA Approves Clinuvel Drug, Aclaris Files Patent Lawsuit Against Taro, Viela Out-Licenses Autoimmune Disorder Drug - BenzingaThe Daily Biotech Pulse: FDA Approves Clinuvel Drug, Aclaris Files Patent Lawsuit Against Taro, Viela Out-Licenses Autoimmune Disorder Drug - Benzinga
www.benzinga.com - October 9 at 8:20 AM
Neuralstem regained Nasdaq compliance. Now it’s pushing forward with clinical trials. - Washington Business JournalNeuralstem regained Nasdaq compliance. Now it’s pushing forward with clinical trials. - Washington Business Journal
www.bizjournals.com - September 25 at 3:30 AM
14 Healthcare Stocks Moving In Tuesdays Pre-Market Session - Benzinga14 Healthcare Stocks Moving In Tuesday's Pre-Market Session - Benzinga
www.benzinga.com - September 24 at 5:28 PM
Neuralstem Announces Last Subject Enrolled in Phase 2 Clinical Trial Evaluating Human Neural Stem Cells in Chronic Stroke Patients - PRNewswireNeuralstem Announces Last Subject Enrolled in Phase 2 Clinical Trial Evaluating Human Neural Stem Cells in Chronic Stroke Patients - PRNewswire
www.prnewswire.com - September 24 at 5:28 PM
Neuralstem Announces Last Subject Enrolled in Phase 2 Clinical Trial Evaluating Human Neural Stem Cells in Chronic Stroke PatientsNeuralstem Announces Last Subject Enrolled in Phase 2 Clinical Trial Evaluating Human Neural Stem Cells in Chronic Stroke Patients
finance.yahoo.com - September 24 at 5:28 PM
Neuralstem regained Nasdaq compliance. Now it’s pushing forward with clinical trials.Neuralstem regained Nasdaq compliance. Now it’s pushing forward with clinical trials.
finance.yahoo.com - September 24 at 5:28 PM
Form 10-Q Neuralstem, Inc. For: Jun 30 - StreetInsider.comForm 10-Q Neuralstem, Inc. For: Jun 30 - StreetInsider.com
www.streetinsider.com - August 14 at 11:15 PM
Neuralstem Reports Second Quarter 2019 Fiscal Results - PRNewswireNeuralstem Reports Second Quarter 2019 Fiscal Results - PRNewswire
www.prnewswire.com - August 14 at 11:15 PM
Neuralstem Reports Second Quarter 2019 Fiscal Results - Yahoo FinanceNeuralstem Reports Second Quarter 2019 Fiscal Results - Yahoo Finance
finance.yahoo.com - August 14 at 8:07 AM
Neuralstem Reports Second Quarter 2019 Fiscal ResultsNeuralstem Reports Second Quarter 2019 Fiscal Results
finance.yahoo.com - August 14 at 8:07 AM
Neuralstem Announces Nasdaq Hearings Panel Grants Request For Continued ListingNeuralstem Announces Nasdaq Hearings Panel Grants Request For Continued Listing
finance.yahoo.com - August 7 at 8:08 AM
Neuralstem closes $7.5M capital raiseNeuralstem closes $7.5M capital raise
seekingalpha.com - July 31 at 6:02 PM
Neuralstem Closes $7.5 Million Underwritten Public Offering - PRNewswireNeuralstem Closes $7.5 Million Underwritten Public Offering - PRNewswire
www.prnewswire.com - July 31 at 8:08 AM
Neuralstem Closes $7.5 Million Underwritten Public OfferingNeuralstem Closes $7.5 Million Underwritten Public Offering
www.prnewswire.com - July 31 at 7:44 AM
U.S. STOCKS ON THE MOVE-Alphabet, Starbucks, Abbvie - NasdaqU.S. STOCKS ON THE MOVE-Alphabet, Starbucks, Abbvie - Nasdaq
www.nasdaq.com - July 27 at 6:00 AM
Neuralstem prices $7.5M underwritten public offering, shares down 33% premarket - Seeking AlphaNeuralstem prices $7.5M underwritten public offering, shares down 33% premarket - Seeking Alpha
seekingalpha.com - July 27 at 6:00 AM
Neuralstem files for upsized equity offering; shares down 4% - Seeking AlphaNeuralstem files for upsized equity offering; shares down 4% - Seeking Alpha
seekingalpha.com - July 26 at 5:09 AM
Neuralstem Announces Pricing of $7.5 Million Underwritten Public Offering - PRNewswireNeuralstem Announces Pricing of $7.5 Million Underwritten Public Offering - PRNewswire
www.prnewswire.com - July 26 at 5:09 AM
Neuralstem files for equity offering - Seeking AlphaNeuralstem files for equity offering - Seeking Alpha
seekingalpha.com - July 25 at 12:16 AM
Neuralstem files for equity offering; shares down 19% premarket - Seeking AlphaNeuralstem files for equity offering; shares down 19% premarket - Seeking Alpha
seekingalpha.com - July 22 at 8:11 PM
This page was last updated on 7/6/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.